WilmerHale's corporate lawyers have a long history of experience with cross-border deals involving mergers and acquisitions, public offerings and capital markets, venture capital, joint ventures and other transactions.

Our team counsels companies across industries, drawing on the firm's internationally recognized life sciences, technology and financial services capabilities, to counsel pharmaceutical companies, medical device developers, software and Internet companies, semiconductor manufacturers, fin tech providers and a wide range of other clients. Our transactional lawyers are backed by regulatory lawyers with deep experience in Committee on Foreign Investment in the United States (CFIUS) and Foreign Corrupt Practices Act (FCPA) requirements, as well as by securities, tax, real estate, antitrust and intellectual property practitioners who are ready to meet the diverse needs of all clients.

Bain, Mick

Mick Bain


+1 617 526 6158 (t)

Bonnes, Andrew

Andrew Bonnes


+1 617 526 6136 (t)

Boot, Jeannette K.

Jeannette K. Boot


+1 212 295 6507 (t)

Borden, Mark G.

Mark G. Borden


+1 617 526 6675 (t)

Bothwick, Jay E.

Jay E. Bothwick


+1 617 526 6526 (t)

Braun, Martin

Dr. Martin Braun


+49 69 27 10 78 207 (t)

Buckland, Peter

Peter Buckland


+1 650 858 6036 (t)

Conahan, Joseph B.

Joseph B. Conahan


+1 617 526 6317 (t)

Publications & News


June 7, 2017

Selected 2017 Life Sciences Transactions

Recognized both globally and nationally for its leading life sciences practice, WilmerHale has more than four decades of experience representing biotechnology, pharmaceutical and medical device companies at all stages of growth, as well as venture capitalists and investment banks.

June 7, 2017

Selected 2017 Strategic Alliances, Joint Venture and Licensing Transactions

Our corporate, licensing, intellectual property and regulatory lawyers regularly handle a broad range of strategic alliance, joint venture, licensing,
collaboration, product development, outsourcing, manufacturing, distribution and similar agreements, including many significant deals that are helping to shape the future of science, technology and commerce.

June 7, 2017

Selected 2017 Technology Transactions

For more than four decades, we have represented technology clients in venture capital financings, public offerings, and mergers and acquisitions; handled their licensing, outsourcing, services, joint venture, development and distribution transactions throughout the world; protected their innovations through patent prosecution, portfolio development and litigation; defended their interests in enterprise-critical litigation; and navigated regulatory issues vital to their success.

April 28, 2017

2017 Corporate Reports

WilmerHale's annual IPO, Venture Capital and M&A Reports offer insights into market conditions and provide comprehensive statistics and analysis that are hard to find elsewhere.

March 1, 2017

Selected 2017 M&A Transactions

In 2016, we advised clients on more than 75 M&A transactions with an aggregate value of approximately $50 billion, providing guidance in areas including corporate, securities, antitrust and tax. Since 2006, we have participated in more than 1,000 mergers and acquisitions with a total value in excess of $400 billion, ranging from sales of VC-backed companies to multibillion-dollar global mergers.

March 1, 2017

Selected 2017 Public Offerings and Rule 144A Placements

In 2016, we handled more than 35 public offerings and Rule 144A placements raising approximately $25 billion, for leading companies in life sciences, technology, financial services, communications and other industries.

March 1, 2017

Selected 2017 Venture Financings As Company Counsel

In 2016, we served as counsel in approximately 250 venture financings raising nearly $3 billion, including some of the largest and most prominent deals of the year.

November 8, 2016

JUVE Ranks WilmerHale Lawyers and Practice Areas in Germany

The recommendations are selected by JUVE based on interviews with clients, lawyers and academics that assess a respective law firm's legal excellence, strategic direction, service orientation and future potential.

September 19, 2016

The Legal 500 UK Recognizes Wilmer Cutler Pickering Hale and Dorr LLP as a Top-Tier Firm

In the 2016 edition of The Legal 500 UK, WilmerHale is named a top-tier firm for dispute resolution - international arbitration and crime, fraud and licensing - fraud: white-collar crime, and is recommended in four other practice areas. The guide also names four partners to its "Leading lawyers" list, and recognizes a total of nine of the firm's London-based lawyers.

September 13, 2016

WilmerHale Advises Thermo Fisher Scientific in €1.6B Eurobond Public Offering

Thermo Fisher Scientific Inc. announced the completion of its public offering of €1 billion aggregate principal amount of 0.750% Senior Notes due 2024 and €600 million aggregate principal amount of 1.375% Senior Notes due 2028 at the issue prices of 99.122% of the principal amount and 99.748% of the principal amount, respectively.

Venture Capital

Examples of our experience include:

  • representing biopharmaceutical company Celtaxsys in a $40 million Series D financing. In connection with the financing, Celtaxsys entered into an award and development agreement with Cystic Fibrosis Foundation Therapeutics and licensed its rights in several Eastern European and Asian countries;
  • representing UK company MirriAd in its $15 million Series A round. MirriAd, which makes technology that enables brands to advertise by integrating into popular TV content and music videos, has an office in India and is expanding in the US;
  • representing Viamet Pharmaceuticals Holdings in investments from US, Irish and other UK-based investors; and
  • representing UXPin, a user experience design tool company with teams in Silicon Valley and Poland, in seed and early-stage financings.

Mergers & Acquisitions

Examples of our experience include:

  • representing UK game-maker NaturalMotion in its $527 million acquisition of Zynga, the world's leading provider of social game services;
  • representing AVIC International Holding (Zhuhai) Company in its $230 million acquisition of California-based Align Aerospace Holding, as well as in its CFIUS and antitrust filings and in obtaining Chinese regulatory approval for the acquisition;
  • representing Bermuda-based Bacardi Limited in its acquisition of Angel's Share Brands, marking Bacardi's entry into the bourbon category; and
  • representing Lufthansa in numerous M&A transactions, including its acquisition of a 30% stake in bmi British Midland, and joint ventures for its cargo and aircraft maintenance businesses.

IPO/Capital Markets

Examples of our experience include:

  • representing Yandex N.V., the operator of the leading Search engine in Russia, in its initial public offering;
  • representing UK-based biopharmaceutical company Summit Therapeutics in its initial public offering;
  • representing Austrian-based client Nabriva Therapeutics in its initial public offering;
  • representing the underwriters in UK-based biopharmaceutical company Adaptimmune Therapeutics plc's initial public offering; and
  • representing Danaher Corporation in a €2.7 billion offering of senior notes.

Strategic Alliances, Outsourcing & Licensing

Examples of our experience include:

  • counseling on the formation of the Star Alliance—the largest airline alliance in the world, comprising more than 15 international carriers;
  • representing TiVo in a Build-Operate-Transfer M&A and outsourcing deal with Ness USA, in which TiVo contracted  Ness to create a dedicated technology facility in Iasi, Romania, from which Ness will provide application development services to TiVo;
  • representing the National Hockey League in its licensing of the NHL Centre Ice television package in Canada;
  • representing Ophthotech in an ex-US licensing and commercialization agreement with Novartis Pharmaceuticals related to the treatment of wet age-related macular degeneration; and
  • counseling Merrimack Pharmaceuticals in an exclusive license and collaboration agreement with Baxter International for the development and commercialization a development-stage drug for pancreatic cancer outside of the United States and Taiwan.